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1.  INTRODUCTION 
 
1.1.1 Acute pancreatitis - pathophysiology and diagnosis. 
Acute pancreatitis (AP) is an inflammatory response to pancreatic insult, which can vary in 
intensity from a mild self-limiting inflammation, to a severe type with high rate of complications, 
significant mortality, and high medical cost. Acute pancreatitis is diagnosed in a patient 
presenting with two of the following  three criteria– severe upper abdominal pain which may 
radiate to the back; a serum lipase or amylase greater than three times normal value; radiologic 
imaging which is consistent with the diagnosis, usually with imaging modalities like ultrasound 
abdomen or computed tomography (CT)1. 
 
1.1.2 Classification – ‘acute’ vs ‘acute on chronic’ pancreatitis. 
By definition, acute pancreatitis occurs in a previously normal gland and has the potential to 
resolve over time without residual damage in exocrine and endocrine function. Pancreatitis is 
classified as ‘acute on chronic’ if an episode of acute pancreatitis is superimposed on a 
background of chronic pancreatitis (as evidenced by changes of chronic pancreatitis on imaging 
studies). 
 
1.1.3 Etiology and pathological classification 
In most cases, the etiological agent is either gallstones or alcohol in excess consumption. The 
critical initiating event is the activation of digestive enzymes in the pancreatic acinar cells. 
Pancreatic inflammation then leads to two broad categories of changes. One that is limited to 
inflammation of the pancreas and peripancreatic tissues without necrosis called edematous 
interstitial acute pancreatitis. The second, more severe type called necrotising acute pancreatitis 
is characterised by necrosis of pancreatic and/or peripancreatic tissues. 
 
1.1.4.Disease course and complications 
About 80% of patients with acute pancreatitis have mild disease and have a good outcome. The 
rest have severe pancreatitis with a high rate of mortality (25%) and significant morbidity. 
 
1.1.5.1 Local complications  
Local complications of pancreatitis include necrosis and fluid collections.If they persist for more 
than 4 weeks, they evolve to form pseudocysts and walled off necrosis respectively. 
Peripancreatic inflammation can also lead to local vascular complications, namely, splanchnic 
venous thrombosis, bleeding or pseudoaneurysm. 
 
1.1.5.2 Systemic complications 
In severe pancreatitis, leukocyte and cytokine mediated distant organ damage leads to the 
development of multiple organ dysfunction syndrome (MODS). Acute lung injury, that can 
clinically manifest as acute respiratory distress syndrome and acute kidney injury are the major 
complications of MODS in acute pancreatitis. 
 
  
1.2.1 Classification of severity. 
Pancreatic damage can leads to a localized and  systemic inflammatory response. Acute 
pancreatitis has been traditionally classified as severe and mild, according to the Atlanta 
classification2based on the absence or presence of local and systemic complications and distant 
organ failure during the entire course of the illness. The Atlanta classification was recently 
modified to include a third group of patients, classified as moderately severe acute pancreatitis, 
who have transient organ failure or have only local complications without persistent organ 
failure. The majority of the patients who develop acute pancreatitis have mild disease. 
 
1.2.2 Prediction of severity 
Severe pancreatitis has to be identified as early as possible to provide more intensive monitoring, 
appropriate therapy and an accurate prognosis. Thus every clinician who treats pancreatitis is 
looking for a tool that is easy to use, that can be used early in the course of illness (ideally at 
admission) and accurately identifies those who have or will develop severe acute pancreatitis. 
 
1.2.3 Predictors of severity 
There are many clinical and laboratory parameters which are used to predict severity in patients 
with acute pancreatitis. These include (a) patient characteristics like age and body mass index 
(BMI),(b)clinical signs  such as shock and tachycardia,(c) bio-chemical parameters such as C-
reactive protein (CRP), (d)imaging studies like chest X-ray and CT scan and (e)composite scores 
such as Ranson’s3 and APACHE-II scoring systems4. 
 
There are  many laboratory markers have been used as predictors of severity. They include 
hematocrit5,CRP6, lactate dehydrogenase,interleukin-6 (IL-6)7,procalcitonin, polymorphonuclear 
leukocyte elastase, phospholipase A2 and urinary trypsinogen activation peptide8. Hydrogen 
sulphide (H2S), the topic of this study, is a new marker which has been shown in animal models 
to correlate with severity of acute pancreatitis. Human studies on the usefulness of H2S in acute 
pancreatitis are scanty. 
 
1.3.1 Hydrogen sulphide (H2S) 
Hydrogen sulphide has been known for centuries for its distinct odour and toxic nature. Recent 
studies have established H2S to be an important ‘gasotransmitter’ in the body, along with nitric 
oxide and carbon monoxide9.  
 
1.3.2 Synthesis and catabolism 
H2S is synthesized in the human body from the amino acids homocysteine, cystathionine and 
cysteine by the action of at least two distinct enzymes: cystathionine-β-synthase and 
cystathionine-γ-lyase. In central nervous system, Cystathionine-β-synthase (CBS) and in the 
cardiovascular system, cystathionine-γ-lyase (CSE) are the key enzymes responsible for the 
endogenous production of H2S. Both CBS and CSE enzymes use substrate as L-cysteine and 
cofactor as pyridoxal-5′-phosphate.10 As the end product of  metabolism, H2S have a negative 
feedback effect on the activity of these enzymes 11.In vivo, H2S is metabolized rapidly by a 
multiple enzymatic processes. Of all these processes, the mitochondrial oxidation mechanism 
represents the most important pathway of H2S catabolism. Finally, H2S is an endogenous 
reducing agent which can be easily consumed by a variety of circulating oxidant species in the 
vasculature such as hydrogen peroxide, peroxynitrite, superoxide radicals and  hypochlorite.12-15. 
Its excretion is mainly by the kidney as free or conjugated sulfate16. 
 
Pancreatic acinar cell expresses both major H2S forming enzymes CBS and CSE. Messenger-
RNA for CSE is expressed in mouse pancreas and pancreas homogenates can convert L-cysteine 
to H2S ex-vivo.  
 
1.3.3 H2S in animal models of pancreatitis 
1.3.3.1 Correlation with severity 
Plasma levels of H2S are increased in mice upon induction of acute pancreatitis. In isolated 
pancreatic acinar cells, the level of H2S and CSE messenger RNA were also significantly 
elevated when stimulated by caerulein17.  Data from animal studies suggest that there is a good 
correlation between H2S levels and the severity of pancreatitis and presence of acute lung injury. 
 
1.3.3.2 Attenuation of inflammation by blockade of H2S production 
The conversion of L-cysteine to H2S in pancreas homogenates is significantly reduced in mice 
which were pre-treated with DL-propargylglycine (PAG)18. PAG is an inhibitor of the H2S -
synthesizing enzyme cystathionine-gamma-lyase (CSE). In addition, treatment of animals with 
PAG (either therapeutic or prophylactic) reduced the severity of pancreatitis as shown by a 
significant reduction of acinar cell injury, necrosis, hyper-amylasemia, myeloperoxidase activity 
of  pancreatic tissue, and by the histological evidence. 
 
As we know, severe acute pancreatitis is associated with lung injury, which is characterized by 
increased MPO activity in lung tissue, sequestration of neutrophils within the lung and 
histological evidence of lung injury. When PAG was administered either Prophylactic or 
therapeutic, it protected mice against lung injury associated with acute pancreatitis as evidenced 
by a significant reduction in MPO activity and by histologically diminished lung injury 18. So, 
there is pro-inflammatory role of H2S in regulating the severity of pancreatitis and associated 
lung injury as evidence by these effects of CSE blockade. 
 
Caerulein-induced acute pancreatitis is associated with a significant increase in various 
chemokines like macrophage inflammatory protein- (MIP-) 1α, monocyte chemoattractant 
protein (MCP)-1, and MIP-2 in both the lungs and pancreas, suggesting their role as  early 
mediators in both local as well as distant inflammatory response. In caerulein-stimulated  
pancreatic acinar cells, PAG induced inhibition of H2S formation reduced CSE messsanger RNA 
expression and also decreased the  levels of MIP 1 α, MIP 2  and MCP 1.17,19.  
 
1.4 Study rationale 
Though many predictors of severity in acute pancreatitis are available, because of low 
specificities and the fact that severe cases of acute pancreatitis are a smaller proportion, the 
positive predictive value of the available tests have been disappointing. H2S seems to correlate 
well with disease severity in animal models. We set out to evaluate whether H2S levels correlated 
with severity in acute pancreatitis and if so how good a predictor of severity it was. 
 
 
 
  
 
 
 
 
        
        REVIEW OF LITERATURE 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. REVIEW OF LITERATURE 
 
2.1 Disease burden 
In acute pancreatitis, the annual incidence ranges from 5 to 50 per 105 persons 20-23. Most of the 
cases of pancreatitis are  mild and self-limiting. Mild pancreatitis accounts for about 80 % of all 
the cases. The overall mortality rate is about 10%24, with higher mortality rates of 25% - 33% in 
severe cases. 
 
2.2 Etiology 
The most common causes of acute pancreatitis are gallstone disease and alcohol abuse, 
accounting for 60–80% of the cases25. Other etiologic factors are hyperlipidaemia, 
hypercalcemia, drugs, ampullary and pancreatic ductal obstruction, tumors, pancreas divisum 
and hereditary pancreatitis26 
 
2.3 Severity assessment and prognostication 
As discussed earlier, acute pancreatitis without local complications or distant organ dysfunction 
is classified as mild. In the presence of local complications and/or persistent organ failure, it is 
classified as severe. Scoring systems such as the Ranson’s score27 and APACHE II 28have a 
sensitivity of 65–75% in predicting the course of the illness, but like composite scores measuring 
multiple pathophysiological parameters, they are complex, need repeated measures and are not 
specific for acute pancreatitis. In spite of these drawbacks, the above mentioned scores are the 
best currently available descriptors of the patient’s status. They provide a snapshot of the 
patient’s status at index evaluation, and with repeated measurements, provide trends which can 
be used for prognostication. They provide the clinician with validated, albeit impractical, tools to 
assess severity and predict outcome.  
 
2.4 Prediction of severity with biomarkers 
Several biomarkers have been studied to try and for predicting the severity of the pancreatitis 
before the patient develops complications of multiple organ dysfunction. These biomarkers are 
either enzymes released from the pancreas or mediators induced by the inflammation in the 
pancreas and distant organs (cytokines and CRP), and have a direct correlation with disease 
severity. 
 
2.4.1 C-reactive protein 
C-reactive protein (CRP) has been well studied and found to be useful. The main drawback of 
CRP is that peak plasma level is reached only after 2-3 days29-30, and low values in patients 
presenting early can be falsely reassuring. CRP values >120 mg/L can detect  pancreatic necrosis 
in 67 to100 % of cases 31. 
 
2.4.2 Hematocrit 
In animal models, it was shown that haematocrit rise occurs earlier than systemic inflammatory 
response or haemodynamic manifestations of acute pancreatitis32-33. A reliable predictor of the 
development of severe acute pancreatitis is admission hematocrit value greater than 47%. Failure 
of admission haematocrit to normalise after resuscitation or within first 24 hrs predicts the 
development of local and systemic complications. In patients with no haemoconcentration within 
first 24 hrs, organ failure is less likely 34. 
 2.4.3 Procalcitonin 
One of the well studied marker of sepsis is Procalcitonin (PCT). It is commonly used as an early 
marker of systemic inflammatory response induced by sepsis and multi-organ failure 35. Infected 
pancreatic necrosis, sepsis and multi-organ failure are the major complications of acute 
pancreatitis. Studies have shown that increased serum levels of PCT may be a reliable early 
predictor of a severe outcome such as infected pancreatic necrosis36-37 
 
2.4.4 Lactate dehydrogenase 
Lactate dehydrogenase (LDH) which is included as one of the criteria in Ranson’s score has also 
been studied independently. In 42 patients with acute pancreatitis studied by Chen et al, serum 
LDH activity was  higher in severe pancreatitis38.On evaluating the isoenzymes, LDH-4 and 
LDH-5  were found to be  increased, however, LDH-2 and LDH-3 are the predominant 
pancreatic isoenzymes, which suggest that the pancreas was not the major source of the 
circulating LDH. In a study done by Uhl and coworkers39on 52 patients (mild 29 and severe 23) 
with pancreatitis, high LDH measurements were noted in 82% of patients with necrotizing 
pancreatitis. 
 
2.4.5 Interleukin-6 and -8 
In response to a tissue injury, macrophages released interleukin 6 (IL-6) which mediates the 
production of various acute phase reactants including CRP. The peak levels of IL-6 are reached 
in 24 hours. It was shown that plasma IL-6 concentrations within 24 hours correlated with the 
mortality rate40-42. IL-8 is also increased in patients with severe disease43-44 It has been suggested 
that, IL-6 and IL-8 are more useful than CRP  within  first 24 hours in predicting the disease 
severity, because  peak levels of both these interleukins are achieved before CRP45.However, 
their validity and superiority over standard scores (APACHE II, Ranson’s, and Glasgow) have 
not been fully investigated. Although there are methods that can measure IL-8 and IL-6 rapidly, 
these facilities are not available in all biochemical laboratories. 
 
2.4.6 Tumour necrosis factor alpha 
Tumour necrosis factor (TNF) α, a macrophage-derived cytokine, play a major   
pathophysiological role in inflammation and sepsis46.It is a non-specific marker. In large 
comparative studies, the value of TNF-α in predicting severity has not been assessed. However, 
there are few studies which suggest a correlation between  TNF-α levels and  acute severe 
pancreatitis47-48. 
 
2.4.7 Trypsinogen activation peptide 
In cases of acute pancreatitis, inappropriate trypsinogen activation in the pancreas results in the 
release of trypsinogen activation peptide (TAP) into the urine, plasma, and peritoneal cavity. 
Thus, it seems that plasma trypsinogen activation peptide concentration is one of the best and 
earliest markers of acute pancreatitis 49-50.TAP has been shown to closely correlate with severity 
of disease51 Since it is rapidly excreted in urine, it can be conveniently measured in a urine 
sample. Elevated urinary TAP (>10 ng/ml) correlates with the severity of disease.50 This test can 
be applied to the patients presenting within 12 hours of pancreatitis. The negative predictive 
value approaches 100% and the positive predictive value of an elevated TAP is 80% 51.  
 
Ransons’s and APACHE II scores and CRP  are the most effective methods in routine use 
between 2nd  and 3rd day and have not yet been replaced by the newer laboratory markers. 
Ranson’s signs more than or equal to 3 and APACHE-II points of more than 8 are considered as 
unfavourable early prognostic signs and as severe pancreatitis. 
 
Ranson’s Criteria -parameters used: 
At admission: 
A  Age more than 55 years 
B White blood cell count more than16 x 103  cells/mm3 
C Blood glucose more than 200 mg/dL 
D Serum AST more than 250 IU/L 
E Serum LDH more than 350 IU/L 
Within 48 hours: 
1. Serum calcium less than 8.0 mg/dL 
2. Drop in Hematocrit of more than 10% 
3. Hypoxemia PO2 less than 60 mmHg 
4. BUN increased by 5 or more mg/dL  after Intravenous fluid hydration 
5. Base deficit more than 4 mEq/L 
6. Sequestration of fluids more than  6 L 
For gallstone pancreatitis, the parameters are: 
At admission: 
1. Age more than 70 years 
2. White blood cell count more than 18 x 103 cells/mm3 
3. Blood glucose more than 220 mg/dL 
4. Serum AST more than  250 IU/L 
5. Serum LDH more than 400 IU/L 
Within 48 hours: 
1. Serum calcium less than 8.0 mg/dL 
2. Drop in Hematocrit more than 10% 
3. Hypoxemia PO2 less than60 mmHg) 
4. BUN increased by 5 or more mg/dL after Intravenous fluid hydration 
5. Base deficit more than 5 mEq/L 
6. Sequestration of fluids more than 4 L 
The APACHE-II system assigns points for 12 physiologic variables which are heart rate, 
temperature, respiratory rate, mean arterial blood pressure, serum potassium, sodium, creatinine, 
arterial pH, oxygenation, white blood cell count, hematocrit and Glasgow Coma Scale. 
 
2.5 Hydrogen sulphide 
For the past few years research has been carried out in an attempt to assess the role of hydrogen 
sulphide in physiology and diseases particularly inflammatory conditions like acute pancreatitis. 
 
2.5.1 Introduction 
Hydrogen sulphide has been known since early times. The chemistry of H2S has been studied 
since the year1600.Hydrogen sulphide (H2S) is a water soluble inflammable and colourless gas 
with the rotten eggs smell. Hydrogen sulphide often results from anaerobic digestion from 
the bacterial breakdown of organic matter in sewer and swamps in the absence 
of oxygen. H2S also occurs in natural gas, some well waters and volcanoes too. It is also 
produced in human body in small amount that acts as signalling molecule. 
 
2.5.2 Synthesis, regulation and catabolism 
In vivo, its formation is catalysed predominantly by the cystathionine-γ-lyase (CSE) and 
cystathionine b-synthase (CBS), which uses the amino acids such as L-cysteine, L-homocysteine 
and L-cystathionine52. Endogenous H2S can be synthesized by the desulfuration of 
cystine/cysteine by three enzymes; Cystathionine beta synthase, Cystathionine gamma lyase and 
mercaptopyruvatesulfurtransferase.CBS and CSE are mainly produced in the cytosol53-58.Both 
enzymes use cofactor as pyridoxal-5′-phosphate and substrate as L-cysteine59. H2S exerts a 
negative feedback effect on the activity of these enzymes 60. H2S in vivo is metabolized rapidly 
by multiple enzymatic processes. Finally, H2S is an endogenous reducing agent which can be 
easily consumed by a variety of circulating oxidant species in the vasculature such as superoxide 
or hydrogen peroxide, peroxynitrite and hypochlorite.12-15. Its excretion is mainly by the kidney 
as free or conjugated sulfate. 
 
In mammalian serum, physiological concentration  have been reported to be in the 30–100 µM 
range, whereas it is as high as 160 µM in brain. H2S can exert toxic effects on some organs at 
concentration above 250 µM 61-63.Endogenous levels of H2S have been measured in the 
circulatory system with rat serum being reported to contain ~46uM  H2S64. 
 
2.5.3 Role in physiological functions 
Hydrogen sulphide has many important roles in human body. As a gaso-transmitter, H2S  
passes through cell membranes without using specific transporters and exerts many biological 
effects  such as cytotoxic effects or cytoprotective actions65-71CBS expression has been found in 
all parts of the brain, liver and pancreas. In mouse pancreas, CBS is ubiquitously distributed, but 
CSE was found mostly in the exocrine and in very small amounts in the freshly prepared islets. 
However, high glucose increased the CSE expression in the beta-cells 72.These enzymes are 
constitutively expressed in many tissues and their expression can be upregulated at the site of 
injury. In some tissues of the body, both CBS and CSE are required for H2S biosynthesis, 
whereas in others, only one of them is sufficient.73  
 
The potent vasodilatory effect of H2S in large blood vessels and portal vein has been proven in 
studies on rats74.Its relaxation effect on resistance arterioles has also been reported75.H2S  can 
relax vascular and non-vascular smooth muscle.  
 
In hippocampus of brain, it might have a role in the induction of long-term potentiation76 and the 
hypothalamic release of corticotrophin releasing hormone77. H2S facilitates long term 
potentiation in active synapses suggesting a role in neuromodulation and active learning. H2S can 
also have significant effects on mitochondrial respiration, and can even serve as a metabolic fuel 
for  tissues like colon and liver 78. 
 
2.5.4 Role in inflammation 
H2S is also is an endogenous anti-inflammatory agent. It is reflected through various studies.H2S 
seems to play an important role as a modulator of leukocyte adherence to the vascular 
endothelium. Administration of β-cyanoalanine, an inhibitor of CSE  causes a rapid increase in 
the adherence of white blood cells (WBC) to the vascular endothelium in mesenteric venules of 
rats79. In studies, H2S donors have been shown to suppress WBC adherence to the vascular 
endothelium induced by superfusion of veins with a pro-inflammatory peptide79.These inhibitory 
effects were reversed by glibenclamide, suggesting the role of ATP-sensitive K+ (K+ATP) 
channels. The up-regulation of adhesion molecule expression on leukocyte and endothelium that 
was observed following aspirin use was suppressed by pre-treatment with an H2S donor80. H2S 
donors also attenuated pain, which is also one of the hallmark feature of inflammation, and this 
effect was mediated through activation of K+ATP channels81. In rats, H2S donors have been shown 
to decrease the visceral pain.82-83. 
 
On the other hand, H2S may have a pro-inflammatory role. H2S via its vasodilatory properties 
causes fall in blood pressure and cardiac output. The levels of H2S have been found to have  
increased in endotoxic and septic shock84. 
 
H2S has been shown to regulate number of physiological functions like inflammation, 
nociception, blood pressure, insulin secretion, learning and memory power in part via the 
modulation of KATP channel activity85-88. As such, modulation of endogenous  H2S through 
either  H2S-donor molecules or H2S synthesis inhibitors represent potentially therapeutic targets 
for a variety of diseases where  H2S synthesis is involved, such as chronic inflammation, 
endotoxic or hemorrhagic shock, hypertension, diabetes, obesity and diseases such as arthritis  
and inflammatory bowel disease89-94 
 
2.5.5 Role in gastrointestinal inflammation 
One of the mechanism by which NSAIDs induce gastrointestinal toxicity is the modulation of 
endogenous gastric H2Ssynthesis. Both H2S synthesizing enzymes namely CBS and CSE are 
variably expressed in gastrointestinal tract. NSAIDs reduced H2S production by reducing the 
expression of CSE in the gastric mucosa and aggravating acid-induced gastric ulcer formation95. 
Gastroprotective  effects mediated by NaSH (an H2S donor) act by reducing neutrophil 
infiltration in the gastric mucosa and by reducing adherence of WBC to the vascular 
endothelium. Reduced H2S synthesis may also play a role in the development of the ulcerative 
colitis. In an experiment done by Wallace et al on a rat model, with the development of colitis, 
the colonic H2S synthesis initially increased in response to trinitrobenzenesulfonic acid (TNBS), 
and then later decreased with colonic damage, whereas inhibition of CBS enzyme aggravated the 
colitis96. 
 
2.5.6 Role in inflammatory joint disease-  
In patients of rheumatoid arthritis, synovial fluid contained up to four-fold concentrations of H2S 
than in paired plasma samples and more than two-fold-higher H2S levels than synovial fluid 
aspirates from patients with non-inflammatory arthritides 97.Synovial fluid H2S concentrations 
was negatively correlated with Synovial total WBC Counts. It could represent a novel index of 
disease activity in the inflamed joint. 
 
2.5.7 Role in renal ischemic-perfusion injury 
In porcine model of non-heart beating donor kidney, H2S has been shown to improve the 
outcome of ischemia-reperfusion injury. In a study by Hosgood SA et al, kidneys were subjected 
to warm ischemia followed by cold storage and then H2S donor sodium hydrogen sulphide was 
given before and after reperfusion with autologous blood, it was found that H2Ssignificantly 
improved the markers of renal function. Renal blood flow improves because of vasodilatory 
effect of H2S. There may be a possible role of H2S in renal transplant recipients98. 
 
2.5.8 Role of Hydrogen sulphide in pancreas 
There are many studies that have suggested that H2S  has both pro and anti-inflammatory 
properties in pancreatitis, depending largely on the experimental conditions. It has been proposed 
that low concentrations (NaHS- 5 and 10 µM) of H2S, have a protective effect99.Jenab N 
Sidhapuriwala et al also studied the pre-treatment with NaHS in mice with caerulein induced 
pancreatitis and found that it was associated with decreased inflammation in both pancreas and 
lung100.On the other hand higher concentrations of NaHS (100 µM) induced inflammation in the 
acini101-102. In experimental pancreatitis, there was upregulation of CSE expression and H2S 
production whereas inhibition of endogenous H2S formation with DLpropargylglycine (PAG), a 
CSE inhibitor, reduces the severity of  pancreatitis and affords protection against the lung injury 
in mice103. 
 
 H2S has been reported to induce apoptosis in both exocrine and endocrine cells of the 
pancreas101. The mechanism behind it is the activation of effector  caspase -3 and initiator  
caspase- 8 and 9 which leads to induction of apoptotic cascade, upregulation of pro-apoptotic  
proteins and down regulation of anti-apoptotic proteins.  H2S has also been shown to have anti- 
apoptotic effects on pancreatic endocrine cells which was evident when high glucose induced 
mouse islet cells apoptosis, which was suppressed by 100 uM of NaHS and 3 mM L-Cysteine104 
  H2S has been shown to modulate pancreatic nociception. Nishimura et al showed that pancreatic  
H2S most probably targets T-type Ca(2+) channels, and that endogenous H2S produced by CSE 
acting on these Ca(2+)channels are involved in pancreatitis-related pain105. 
 
 
2.5.9 Role in pancreatitis associated lung injury 
There are studies which demonstrated the role of H2S in pancreatitis associated lung injury. 
Madhav Bhatia et al demonstrated that administration of PAG protected animal against acute 
pancreatitis associated lung injury which was evidenced in their study by a significant 
reduction  of lung myeloperoxidase activity and by histological evidence 106.The exact molecular 
mechanisms by which H2S modulates inflammatory signalling in the lung are unknown. H2S has 
potential role in acute lung injury and ARDS through different mechanism like regulation of 
leucocyte activity and neurogenic inflammation. It has both proinflammatory and anti-
inflammatory actions which were demonstrated in various studies.PAG, a CSE inhibitor which 
inhibits H2S synthesis suppresses the overproduction of pro-inflammatory cytokines and 
chemokines in sepsis, which is a key feature of systemic inflammation and also attenuates acute 
lung injury caused by sepsis or endotoxemia. Its anti-inflammatory action has been shown in 
murine model in which lung injury was induced by smoke fumes, intraperitoneal administration 
of NaHS an H2S donor alleviates lung injury, improved survival and histological condition of 
lung107.However in Oleic acid induced lung injury model, administration of H2S donors in rats 
down-regulated the production of pro-inflammatory IL-6 and IL-8 in lung but increased the level 
of anti-inflammatory IL-10 in plasma and lung, thus alleviating lung edema, PMNs infiltration in 
lung and severity of lung injury108.The protective effect of H2S in acute lung injury has been 
reported in some models of lung injury caused  by smoke inhalation whereas the opposite  
findings are usually obtained in lung injury caused by systemic insults such as sepsis and 
pancreatitis. High dose of H2S donor tends to aggravate inflammation in lungs and while the low 
dose (or slow release) of H2Sdecreased inflammation. The discrepancy in the role of H2S in lung 
injury may be due to the different doses of H2Sdonors used and different animal models. 
 
2.5.10 Role in sepsis 
Lipopolysaccharide (LPS), a bacterial toxin which has been shown to induce activation and 
upregulation of vascular K-ATP channels resulting in hypotension109-110. H2S act as an 
endogenous ligand for KATP channels and induces vasorelaxation in vascular endothelium, 
reflecting its role in endotoxic shock111. In septic shock, plasma H2S levels were also reported to 
be elevated. It was found that administration of  PAG, a CSE inhibitor to LPS treated animals, 
decreases  plasma H2S  levels and increased survival suggesting that increased plasma H2S 
concentration in blood was playing a role in hemodynamic instability observed in septic 
shock.112 
 
 
2.5.11 H2S donors 
Various H2S salts are used for the study purpose in animal models. They are either fast or slow 
H2S donors. The fast H2S donors, Na2S and NaSH, result in an instantaneous release of H2S 
when added to aqueous solutions113. It is very unlikely that under normal physiological 
condition, the tissues are ever exposed to such a rapid local concentration of H2S, since 
endogenously produced H2S through action of CBS and CSE is relatively slow and sustained114-
115. Injection of these salts (fast H2S donors) into animal models results in a small increase in 
plasma H2S concentrations that too over a very short period of time. To overcome the above 
problem, slow releasing H2S donors came into existence. ADT-OH {5-(4-hydroxyphenyl)-3H-1, 
2-dithiole-3-thione} a derivative of  NSAID molecules is a slow releasing H2S donor116. The 
problem with this molecule is that biological effects associated may be due to the dithiolethione 
moiety itself, rather than released H2S. Therefore, care should be taken to interpret the data.  
GYY4137 is another a very slow-releasing H2S donor compound that releases two molecules of 
H2S  and has been shown to induce vasodilator activity in vivo via KATP channel-dependent 
mechanisms in hypertensive rats117.Its decomposition product are inactive so allowing its use to 
study the physiological effects of slow releasing H2S in inflammatory condition. 
 
2.5.12 Is H2S a pro-inflammatory or an anti-inflammatory mediator? 
Its role in inflammation is still a debate. Now, it is becoming apparent that H2Shas a dual role in 
inflammation and current studies vary in opinion, largely based on rate of release, dose and type 
of H2S donor used The  pro-inflammatory role of H2Swas shown in animal models such as LPS 
induced endotoxemia, pancreatitis, hemorrhagic shock118 and  burns injury119. In all of these 
studies pretreatment with PAG, an inhibitor of H2S synthesis, protected animal against injury and 
administration of fast H2Sdonors like NaHS aggravated the injury.  On the other hand, its anti-
inflammatory role was shown in animals gastric and colonic epithelium where Lawesson 
reagent(a sulfide donor) or NaHS at low dose  have been studied120.  The slow release H2Sdonor 
GYY4137 has also been shown to protect mice against LPS induced endotoxemia. There are also 
conflicting reports on the role of H2S on leukocyte rolling and adhesions. Previous studies have 
shown that H2S both positively and negatively regulate leukocyte activation and migration121. 
 
2.5.13 Human Studies 
Most of the studies on the role of H2S in pancreatitis were done on rats. The role of H2S in 
humans is not well studied. To the best of our knowledge, the first human study on the role of 
H2S in acute pancreatitis was done by Eric WL Wee et al in which they have shown that  H2S  
and substance P were involved in inflammatory response in acute pancreatitis and their levels 
correlated with the severity in early hours of pancreatitis122.  
 
2.5.14 Future trends 
Pharmacological research related to H2S is an emerging field, which is likely to produce a 
number of therapeutic possibilities. There are drug candidates which are in early stages of  
development. H2S-related future therapeutic avenues might also include genetic approaches and 
drugs using overexpression of H2S-producing enzymes as a therapeutic modality might be 
explored. 
 
The present study is first of its kind to study the role of H2S in patients with acute pancreatitis in 
routine clinical practice who seek medical care several days after onset of pain. Our hypothesis is 
that H2Sbiosynthesis is increased in pancreatic inflammation and that elevation of H2S levels in 
blood would correlate with the severity of pancreatitis, providing us with a tool that will help 
clinicians by improving prognostic accuracy and by early identification of patients who will need 
more intensive monitoring. 
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3. AIM 
 
To establish the value of hydrogen sulphide as new marker for severity and prognosis in acute 
pancreatitis. 
 
4. OBJECTIVES 
 
1. To prospectively enrol adult patients admitted with acute pancreatitis and assess severity of illness to 
classify them as mild or severe pancreatitis 
2. To investigate the correlation between hydrogen sulphide levels and severity of illness. (Primary 
objective) 
3. To investigate the changes in hydrogen sulphide levels during the course of the illness and correlate with 
the course of the disease, by estimating it at admission, after initial resuscitation (48 hrs later) and at 
discharge. 
4. To investigated whether H2S levels correlate with specific organ dysfunction  namely, acute lung injury, 
haemodynamic compromise, renal dysfunction or infections 
 
  
  
    
 
      MATERIALS AND METHODS   
 
 
 
 
 
 
 
 
 
 
 
 
5.MATERIALS AND METHODS  
 
5.1 Recruitment 
5.1.1 Site and duration 
The study was a prospective single centre study, conducted at the Christian Medical College 
Hospital, Vellore, Tamil Nadu, India, from July 2012 to September 2013 in the Department of 
GI sciences. The study protocol was approved by Institutional Review Board of the institution 
and the registration number was 7914 dated 4-7-12. 
 
5.1.2Participants 
All patients who were admitted with the diagnosis of acute pancreatitis were enrolled. The 
diagnosis was made if the patient fulfilled two out of the following three criteria. 
1. Pancreatic type abdominal pain 
2. Serum lipase or amylase more than 3 times normal 
3. Imaging study (USG or CT) suggestive of acute pancreatitis 
Patients of either sex between the ages of 12 and 80 were included. Written and informed 
consent was taken from either patients or their relatives prior to enrolling in the study. 
 
5.1.3 Exclusions 
Pregnant females were excluded. Patients with a diagnosis of chronic pancreatitis, pseudocyst or 
pancreatic tumours were also excluded. 
 
5.2 Management  
All patients diagnosed to have acute pancreatitis were admitted without delay. Every attempt was 
made at admission to define the etiology of pancreatitis. The patients were asked about history of 
alcohol use, drugs or trauma.   
 
The patient were resuscitated with intravenous fluids and provided adequate analgesia. Vital 
parameters were monitored closely and patients were triaged to a high dependency unit if there 
were features of local complications or multi organ dysfunction, either at admission or at any 
time during the course of the hospital stay. Intensity of patient monitoring varied from twice 
daily if the patient was stable, to continuous monitoring in the ICU if critically ill. Naso-jejunal 
feeding was initiated if the patient was unable to tolerate oral feeding 4 days after admission. 
Antibiotics were initiated if there was clinical suspicion of sepsis but continued only if proven by 
cultures. 
 
5.3 Laboratory tests 
Liver function tests, calcium, lipid profile and ultrasound of the abdomen were done to determine 
the etiology .Other standard tests at admission included complete blood count, renal function, 
electrolytes, glucose, C-reactive protein, lactate dehydrogenase, chest x-ray and arterial blood 
gas. A CT scan was done selectively after 48 hours of onset of symptoms if it was deemed to 
contribute to treatment decisions. 
 
5.4 H2S estimation 
5.4.1 H2S estimation time points 
Within 24 hrs after admission, 2-3 ml of blood was collected in EDTA tubes and sent to the 
laboratory for estimation of H2S levels. After 48hours a second blood sample was collected for 
analysis. A third blood sample was collected at the time of discharge. 
 
5.4.2 Procedure for H2S estimation 
Due to its volatile nature, H2S estimation was carried out immediately after sample collection. 
Hydrogen sulphide level in plasma was measured spectrophotometrically. The blood sample was 
aliquoted and 100µl mixed with 50µl of distilled water in micro-centrifuge tubes which also 
contained 300µl of zinc acetate (1% w/v) to trap H2S. The reaction was stopped after 5 min by 
addition of  200µl of N, N-2dimethyl-p-phenylenediamine sulphate (20mM in 7.2 M HCl),  
followed immediately by addition of 200µl of FeCl3 (30mM in 1.2 M HCl). For about 20 
minutes, mixture was kept in dark. In order to precipitate protein from the samples, 150µl of 
trichloroacetic acid (10% w/v) was added. It was then centrifuged for 10 minutes at 10,000 rpm. 
The absorbance of the resulting supernatant was measured at 670 nm using a 96-well plate reader 
.All samples were assayed in duplicates. Mean of two values will be taken for final calculation. 
±0.005 – 0.01 O.D (optical density) variations is considered normal. If it exceeds this variation, 
experiment will be repeated. Since, the assay was standardized beforehand regarding amount of 
starting material we did not have to repeat any assays.H2S concentration in the plasma was 
calculated against the calibration curve of standard H2S solutions (NaHS: 3.125-100 µM)123.  
 
  
5.5 Definitions 
5.5.1 Severity of pancreatitis 
In 1992, the Atlanta symposium classified acute pancreatitis as ‘mild’ and ‘severe’ on the basis 
of certain criteria, which have come to be known as the Atlanta criteria (Table-1). This 
classification (and not the revision of 2012) was used in this study. 
  
AAAA  
  I   Organ Failure 
   1.    Systolic blood pressure  less than 90 mm Hg 
   2.    Serum creatinine  more than 2 mg/dl 
   3.    Hypoxemia i.e PaO2 equal or less than 60 mm Hg 
   4.    Gastrointestinal bleeding more than 500 mL/24 hr 
 
   
  
II    Local Complications either in the form of necrosis, abscess or pseudocyst 
 
III  Unfavourable early prognostic signs  
       A. APACHE II points more than 8            
       B. Ranson’s signs equal to or more than 8  
     
     
      
      
Table-1  Atlanta criteria for severe acute pancreatitis. 
 
 
5.5.2 Alcohol related acute pancreatitis 
Alcohol was accepted as the etiological factor when gall stones was ruled out by ultrasound 
abdomen and there was a history of heavy alcohol intake within three to four days of admission 
or a history of prolonged alcohol abuse, greater than 80 g/ day, with further intake in the four 
days prior to admission. 
 
5.5.3 Hypercalcemia induced pancreatitis 
Acute pancreatitis was attributed to hypercalcemia if the serum calcium was more than 12 mg/dl 
(normal range 9-10.5 mg/dl) in the absence of gallstones or alcohol abuse. 
 
5.5.4 Gallstone-induced pancreatitis 
Gallstones were accepted as etiological factor if imaging, either USG abdomen or CECT 
abdomen, was suggestive of gall bladder stones or common bile duct stone and /or blood tests 
showed deranged liver function test (high bilirubin > 2 mg/dl or transaminitis i.e ALT > 2 times 
normal)in a patient with acute pancreatitis. 
 
5.5.5 Acute fluid collection 
Acute fluid collection was defined as fluid located near or in the pancreas, and lacking a definite 
wall, typically occurring early in course of acute pancreatitis. 
 
5.5.6 Sepsis syndrome 
Sepsis-It is the systemic response to infection and is defined as the presence of SIRS in addition 
to a presumed or documented infection 
Systemic inflammatory response syndrome (SIRS) is defined by presence of two or more of the 
following: 
1. Fever of more than 100.4°F or less than 96.8°F. 
2. Heart rate more than 90  per minute 
3. Respiratory rate of more than 20 per minute or arterial carbon dioxide tension (PaCO2) of 
<32mm Hg 
4. Total leukocyte count i.e.>12 x 103/µL or < 4 x 103/µL or >10% band forms) 
 
5.5.7 Mechanical ventilation 
Patients requiring endotracheal intubation and invasive ventilatory support. 
 
5.5.8 Acute lung injury (ALI) 
Acute lung injury was defined as hypoxemia (PaO2<60 mmHg or PaO2/FiO2<300 mm Hg) with 
bilateral pulmonary infiltrates on chest X-ray.                   
 
5.5.9 Acute kidney injury (AKI) 
Acute kidney injury was defined as rapid deterioration in kidney function within 48 hours of 
admission, with an  absolute increase in serum creatinine > 0.3 mg/dl or percentage increase in 
serum creatinine more than 50 %,  and reduction in urine output  to < 0.5 ml/kg/hr for more than 
6 hours. 
 
5.6 Statistical methods 
5.6.1 Sample size 
Sample size was calculated on the basis of a previous human study.  In the study by Eric WL 
Wee et al, 35 patients were studied.Only patients who presented within 72 hours of onset of 
symptoms were included. Acute pancreatitis was classified as severe in 19 and mild in 16 by the 
Atlanta criteria. The H2S level measured at 0-24 hours after admission, was significantly 
different between patients who had mild and patients who had severe pancreatitis; mild34.3 
(±21.1) vs. severe 189.4(±158.9), (p=0.004). To replicate such a large difference, a sample size 
of 1 in each group is sufficient for a study with a power of 0.80 and a confidence level of 0.95. 
Since the majority patients presenting to our hospital have variable duration of symptoms, often 
more than 3 days prior to admission, we decided to recruit 20 patients in each arm. Based on the 
previous year’s admission data, 40% of acute pancreatitis was predicted to be of severe type. 
Thus, a sample size of 50 was calculated including both mild and severe cases. We also expected 
instances in which H2S estimation would be not possible due to poor sample quality and delays 
in sample transport and analysis. It was decided to continue recruitment till a minimum of 50 
satisfactory samples was collected for 1st time point of H2S estimation (i.e. within 24 hours of 
admission). 
 
5.6.2 Planned data analysis 
Results will be expressed as mean and median with appropriate measures of dispersion.If the 
data does not satisfy the assumption of normality a non-parametric approach will be used. To 
calculate paired differences Wilcoxon signed rank test will be used. Mann-Whitney u-test will be 
used to compare groups. 
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6. RESULTS 
6.1 Patient recruitment 
 
Figure:1      Flow chart showing recruitment of cases of acute pancreatitis. 
 
A total of 110 patients were admitted with a diagnosis of acute pancreatitis during the study 
period. Recruitment of cases is shown in figure1. In 37% of the patients the H2S estimation could 
not be carried out due to various logistic and technical reasons. Round the clock laboratory 
staffing was not available to conduct the H2S estimation procedure. Since the estimation could not 
be done on stored samples, the test was not carried out on patients who were admitted during 
weekends or on national holidays. H2S estimation was not carried out in samples which either did 
not reach the laboratory within 1 hour of collection or had evidence of hemolysis.  
Total number of acute 
pancreatitis during study 
period 
110
Total number analysed 
55
Mild acute pancreatitis 
32
Severe acute pancreatitis 
23
Exclusions
Pregnancy 2
Pancreatic pseudocyst 3
Chronic liver disease 1
Patient s whose samples could not be 
analysed due to logistic and technical 
reasons 41
DIscharged on request 1
Discharged agaist medical advice 2
Short duration of stay 5
Other reasons for non-inclusion included patients with mild pancreatitis who were well and were 
discharged within 24 hours, and patients who were discharged at the request of the family even 
though they were advised to have in-hospital care. Two pregnant women,3 patients with 
pseudocysts and 1 patient with acute on chronic liver failure were also excluded. Of the 55 
patients who were included, three H2S estimates (i.e. at admission,48hrs and at discharge) were 
available for 34 patients and two (i.e. at admission and 48 hrs) for 50 patients. 
6.2 Patient characteristics 
DEMOGRAPHICS PATIENTS (N=55) 
Age (years) 41.6(Mean)(Range-18-80 yrs) 
Sex (male/female) 43/12 
BMI(Kg/m2) 24.63 (Mean)(Range-18.2-36.8) 
Table-2 Patient characteristics (age, sex and body mass index) 
 
 
DAY OF PRESENTATION AFTER THE 
ONSET OF PANCREATITIS 
CASES (N=55) 
Day 1 2 
Day 2 14 
Day 3 20 
Day 4 6 
Day 5 8 
Day 6 5 
Table: 3   Day of onset of pancreatitis and presentation in the study patients. 
 A total of 55 patients of acute pancreatitis were enrolled in the study, of which forty three were 
male and 12 were female. Age of patients included ranged between 18-80 yrs,the mean age was 
41.6 yrs. Mean body mass index(BMI) was  24.63 kg/m2 (range=18.2-36.8 kg/m2).In mild 
pancreatitis cases,20 patients(62.5%) had normal BMI (18.5-24.9 kg/m2) and 12 patients(37.5%) 
were overweight (BMI > 25 kg/m2).Among severe cases,11 patients(47.8%) had normal BMI and 
12 patients (52.17%) were overweight. Figure 2 & 3.Table 2 . 
In our study, most of the patients i.e 36.3 % (n=20) presented to us on day 3rd of pancreatitis.14 
patients presented on day 2nd of pancreatitis. Only 2 patients were presented to us on day one of 
pancreatitis. Out of all 55 patients, 42 patients presented on or before 4rth day of pancreatitis. Rest 
13 patients presented after day 4.None of the patient included in the study presented after day 6. 
Table 3 
 
 
Figure :2Mild acute pancreatitis. Normal BMI n=20. Overweight n=12 
62%
38%
MILD CASES n=32
NORMAL BMI OVERWEIGHT
  
 
Figure:3 Severe acute pancreatitis. Normal BMI n=11. Overweight n=12. 
 
6.3 Etiology of pancreatitis 
ETIOLOGY NUMBER OF CASES(%) 
Alcohol 25(45.5%) 
Gallstones 15(27.3%) 
Post ERCP 1(1.8%) 
Hypercalcemia 1(1.8%) 
Idiopathic/unknown 13(23.6%) 
 
Table-4  Etiology of acute pancreatitis 
 
48%
52%
SEVERE CASES n=23
NORMAL BMI OVERWEIGHT
  
Figure 4 :Pie chart showing various etiologies of acute pancreatitis. 
 
The most common aetiologywas alcohol in 25 patients (45.5%) and gall stones in 15 (27.3%).The 
cause could not be ascertained in 13 patients, one patient had post-ERCP pancreatitis and one had 
hypercalcemia related to a parathyroid adenoma.(Table 4 and figure 4)  
 
 
 
 
 
45%
27%
24%
2% 2%
ETIOLOGY
ALCOHOL
GALL STONES
IDIOPATHIC
HYPERCALCEMIA
POST ERCP
6.4 Severity of pancreatitis 
 
Figure 5 :Pie chart showing percentages of mild and severe cases of acute pancreatitis. 
 
Among the 55 patients, 32 (58.2%) had mild pancreatitis and 23 (41.8%) had severe pancreatitis, 
as defined by the 1992 Atlanta classification. ( figure 5 ). In our study, the proportion of severe 
cases was more than that described in literature. This was probably due to a referral bias. The 
hospital is a tertiary care centre and severe cases are usually referred to us for management.  
 
 
6.5 Course and complications 
 
58%
42%
SEVERITY 
Mild n=32 Severe n=23
MILD
SEVERE
Table 5–Complications of pancreatitis  
 
6.5.1 Local complications 
Fifteen patients developed local complications. Acute fluid collection, the one most commonly 
noted, was seen in 13. Two patients developed splanchnic venous thrombosis.(Table 5) 
6.5.2 Organ failure 
ORGAN FAILURE- CASES (%) 
Acute lung injury 19(34.5%) 
Acute kidney injury 5 (9.1%) 
LOCAL COMPLICATION-  
Fluid collection 13(23.6%) 
Vascular complication 2(3.6%) 
SYSTEMIC COMPLICATION  
Sepsis 22(40.7%) 
MORBIDITY  
Duration of hospital stay 6(Mean)(Range 1-22) 
Mechanical ventilation requirement 3 (5.5%) 
MORTALITY  
Death 2 (3.6%) 
Nineteen patients(34.5%) had acute lung injury and five (9.1%)had acute kidney injury. Three 
patients (5.5%) required mechanical ventilation. None of the patients underwent dialysis. 
However, two of the study patients who died, hemodialysis was indicated, but was not done. In 
one patient, the reason was shorter duration of stay. He died before dialysis could be initiated and 
for the other patients,the relatives had not given consent for dialysis. 
 
6.5.3 Morbidity and mortality 
Twenty-two patients (40.7%) had sepsis and SIRS, either at presentation or at some time during 
course of hospital stay. Mean duration of hospital stay was 6 days (range-1-22).In 14 patients, 
infectious organism was identified and rest 8 patients, infection was presumed on clinical basis 
(i.e cholangitis, pneumonia, fever pattern and requirement of antibiotics).Most common site of 
infection was urinary tract (n=8) ( Enterococcus was isolated in 3 patients, E.coli in 2, yeast in 2 
and morganella in 1 patient). Blood culture had grown organism in five patients (E coli in 
1,staphylococcus sp in 2,enterococcus in 1 and proteus in 1 patient). Bile culture was positive in 
three patients (E coli in 2 and NFGNB in 1 patient).Sputum culture had grown NFGNB in one 
patient. Three different organisms from three different sites (proteus in blood, enterococcus in 
urine and NFGNB in sputum ) were identified in one patient who died and one other patients had 
two sites of infection including blood and urine. Twenty patients required ICU admission, with 
duration of ICU stays ranging from 1-22 days. Two patients died due to multi organ dysfunction. 
 
 
6.6 H2S estimation – distribution of values 
 
  
Figure:6  Histogram showing admission level of H2S( µmol/L), all cases 
 Figure:7  Histogram showing levels of  H2S( µmol/L)  at admission, of mild and severe cases 
separately. 
The values of H2S at admission did not follow a normal distribution, either for the whole group or 
within mild and severe subgroups. Overall H2S values ranged from 6.07 to 81.43 
(µmol/L)(Figure  6).For severe cases range of H2S values was 6.07 to 74.43( µmol/L). For mild 
cases the range of H2S was 7.14- 81.43(µmol/L). Figure7.  As data did not follow a normal 
distribution, non-parametric methods were used in statistical analysis. 
6.7 Hydrogen sulphide levels at admission 
 
 
Figure 8: H2S levels (µmol/L) at admission in mild (n=32) and severe cases (n=23)of acute 
pancreatitis.                                               
 
The value of H2S estimated within 24 hours of admission was compared between the groups of 
patients with mild and severe pancreatitis. H2S levels at admission were lower in patients with 
mild pancreatitis (median=16.64µmol/L, range= 7.14-81.43µmol/L )compared to patients with 
severe pancreatitis (median=35.7 µmol/L, range=6.07-74.43µmol/L),but the difference was not 
statistically significant(p value=0.339).Figure 8 
6.8 Hydrogen sulphide levels at 48 hours 
6.8.1 Comparison of values at 48 hours 
 
 
Figure 9:H2S levels(µmol/L) at 48 hrs in mild (n=32) and severe (n=23) cases of acute 
pancreatitis     
 
We also evaluated the level of hydrogen sulphide 48 hours after admission. This was based on the 
fact that in many cases the patient’s condition is better assessed after providing adequate analgesia 
and fluid resuscitation.  Plasma H2S levels at 48 hours after admission were higher in the severe 
group (median=28.21µmol/L, range=10-72.86 µmol/L) than the mild pancreatitis group 
(median=16.34  µmol/L, range=3.57-72.86µmol/L). It was not statistically significant (p 
value=0.127). Figure9. 
 
6.8.2 Temporal trends in H2S 
We also analysed the change in H2S after fluid resuscitation by comparing the H2S level at 48 hrs 
to that at admission. Our premisewas that the direction and degree of change in H2S would 
correlate with improvement or deterioration, and provide a clue to the hospital course of the 
patient. Twenty five patients (16 mild cases and 9 severe cases) had decrease in levels at 48hrs, 
while 23 patients (12 mild cases and 11 severe cases) had an increment in levels. The changes 
were found to be bidirectional and did not accurately reflect the patient’s prognosis. 
6.9 Correlation of H2S and duration of symptoms 
 
Figure: 10. Scatter plot of admission H2S values according to duration of pain 
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Figure 11: Admission H2S levels (µmol/L) in cases presenting within 4 days of onset of pain 
(n=42)and after 4 days of onset of pain (n=13) 
 
 Figure 12 : H2S levels (µmol/L) at 48 hrs in cases presenting  within 4 days of onset of pain 
(n=37) and  after 4 days (n=11) of onset of pain. 
 
 
In the present study, we found that hydrogen sulphide levels were higher in those who presented 
earlier after the onset of pancreatitis.(n=42). Patients who presented earlier i.e. on or before 4days 
of onset of pain had higher values of H2S at admission (n=42, median=27.67 Vs n=13, 15 µmol/l, 
p-value=0.032) and at 48 hrs(n=37,median =27.14 µmol/L Vs n=11, median=12.86 µmol/l, p-
value=0.004) compared to those who presented later i.e. after 4 days of onset of pain. Figure11 & 
12. 
 
6.10 Value of H2S estimation in early presenters 
In the study by Eric WL Wee, an extremely clear difference in H2S values was noted between 
mild and severe groups. The patients recruited for that study were all symptomatic for less than 72 
hours. We investigated whether H2S would be a useful discriminator, if we limited its use to those 
presenting early in the course of illness. 
 
 
 
Figure: 13 Comparison of H2S levels (µmol/L) at admission in mild(n=24) and severe 
cases(n=18) presenting  within 4 days of onset of pain 
 In patients who presented within 4 days of onset of pain H2S levels at admission were not 
significantly different between mild and severe cases.( Mild cases, n=24,median= 23.14 µmol/L 
,R=7.14 – 76.43 µmol/L Vs Severe cases n= 18, median=36.78 µmol/L,R=10 – 74.43 µmol/L.P 
value=0.186).Figure: 13 
 
We also analyzed the H2S levels in patients who presented to us within 72 hrs of onset of 
pancreatitis, as previous human study had shown significant difference between mild and severe 
cases in patients within 72 hrs of onset of abdominal pain. However we could not find any 
significant difference between H2S levels in mild and severe cases within 3 days of onset of 
abdominal pain(Mild cases, n= 20,Mean=30.12,Median=26.17 Vs Severe cases, 
n=15,Mean=32.20,Median=35.71)(p value=0.74). 
 
6.11 Correlation of H2S with complications of pancreatitis 
 
6.11.1 Correlation with acute lung injury 
 
 
 
 
 
  
 
Figure 14: H2S levels (µmol/L) at admission in patients with (n=19) and without acute lung 
injury(ALI)(n=36) 
 Figure 15: H2S levels (µmol/L) at 48 hrs in patients with (n=16) and without acute lung 
injury(ALI) (n=32) 
 
Plasma H2S at admission in patients who later developed acute lung injury was not higher than 
those who did not develop lung injury (n=19, median=19.15 µmol/L, r = 6.07 - 74.43µmol/L Vs 
n= 36, median=21.07 µmol/L, r= 7.14 – 81.43µmol/L), and therefore did not  predict acute lung 
injury (p value=0.915). Even at 48 hrs of fluid resuscitation, H2S levels were not significantly 
different between these two groups (n=16,median=24.51µmol/L, r = 10 – 70.86µmol/L Vs 
n=32,median =19.7µmol/L, r = 3.5 – 72.86µmol/L, p value=0.72).Figure 14 and 15. 
We also did not find any correlation between development of lung injury and change in H2S value 
in the first 48 hrs. In patients who developed lung injury an equal number (n=8) showed increase 
and decrease in plasma H2S. 
6.11.2 Correlation with acute kidney injury (AKI). 
 
Figure 16: H2S levels (µmol/L) at admission in patients with acute kidney injury(AKI) (n=5) and 
without acute kidney injury (n=50) in acute pancreatitis 
 
  
Figure 17: H2S levels (µmol/L) at 48 hrs in patients with acute kidney injury(AKI)(n=4)and 
without AKI(n=44) in acute pancreatitis 
 
In five patients who had acute kidney injury, admission plasma H2S was higher than in patients 
who did not have kidney injury, but the difference was not statistically significant (median 
46.43µmol/L, r= 10- 74.43 µmol/L Vs 18.14 µmol/L, r= 6.07-81.43µmol/L, p value=0.30)(Figure 
16).  Similarly, at 48hours there was no difference in H2S levels between the two 
groups(n=4,median=27.5µmol/L, r = 20.16 -70.86µmol/L Vs n=44,median=20.57µmol/L, r = 
3.57 -72.86µmol/L, p value=0.33)(Figure 17).In four out of five patients who had acute kidney 
injury, the H2S levels decreased in the first 48 hours. This was not statistically significant. 
 
 
6.11.3 Correlation with sepsis 
 
 
Figure 18: H2S levels(µmol/L) at admission in acute pancreatitis patients with sepsis (n=22)and 
without sepsis (n=32) 
 
 Figure 19: H2S levels (µmol/L) at48 hrs in acute pancreatitis patientswith sepsis (n=21)and 
without sepsis (n=26) 
 
H2S levels of all patients with sepsis and SIRS were compared with those without. Patients with 
sepsis had slightly higher H2S values at admission (n= 22,median=32.5µmol/L, r= 10-
76.43µmol/L Vs n=32, median=15.9µmol/L, r =6.07-81.43µmol/L) and at 48 
hours(n=21,median=30.2µmol/L, r =8.93-72.86µmol/L Vs n=26, median=19.7µmol/L, r =3.5 – 
62.86µmol/L) when compared to those without. However, the difference was not statistically 
significant (p value=0.18 and 0.32 respectively).Figure 18 & 19 
On serial measurements, no trend which could be used to predict the development of sepsis was 
noted in the first 48 hours. Among patients who developed sepsis, a reduction in H2S was noted in 
12 out of 22 patients, the remaining 10 had increase in levels compared to baseline. 
Duration of hospital stay was in the range of 1 to 22 days. Mean duration of hospital stay was 6 
days. Majority of patients (n=34) had duration of stay of less than or equal to 1 week and 15 
patients had duration of stay of less than 1 week. Out of all 55 patients, twenty patients had 
required intensive monitoring in ICU  
 
6.11.4 Correlation with mortality 
Plasma H2S level at admission in the two patients who expired of multi-organ failure was also  
not different significantly from the patients who survived(Median =28.64 µmol/L Vs 20.7  
µmol/L) 
 
6.12 Other biomarkers 
6.12.1 C-reactive protein 
CRP was done for 43 patients, 25 mild and 18 severe cases. Median CRP values were 
significantly higher in severe cases as compared to mild cases (195 mg/LVs 63.4 mg/L, p value 
<0.001).( Figure 20) In our study, CRP was well correlated with the severity of disease. However, 
CRP levels were not correlated with the H2S values.(Figure:21) 
  Figure: 20 Comparison of  CRP levels (mg/L) in mild and severe cases of pancreatitis. 
 
Figure 21:Scatter diagram showing comparison of H2S (µmol/L) and CRP levels 
6.12.2 LDH 
Lactate dehydrogenase (LDH) was done in 51 patients, mild 30 cases,severe 21cases. Median 
LDH values were  higher in severe cases than in mild cases(778 U/L Vs 498.5 U/L) ,but the 
difference was not statistically significant( p value=0.1).(figure:22).In this study, the levels of H2S 
were also not correlated with LDH values.(figure:23)   
 
 
                    Figure:22 Comparison of LDH levels (U/L) in mild and severe cases. 
              Figure 23: Scatter diagram showing comparison of H2S (µmol/L)  and LDH levels . 
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7. DISCUSSSION 
 
7.1 Characteristics of the patient cohort 
The most common etiology for acute pancreatitis in our study was alcohol (~45%), followed by 
gall stones (~27%).The most common systemic complication observed was acute lung injury (~ 
35 %), followed by acute kidney injury (~ 9 %). Fluid collections were the most common local 
complication though none of the patients developed a pseudoaneurysm. In this study, sepsis was 
noted to be present in about 40 % of patients, and mortality was 3.6%. Severe cases usually 
account for 20-25 % of all cases of pancreatitis, but in our study, the number of cases of severe 
pancreatitis was more (41.8% of the group). This can be attributed to referral bias. 
 
7.2 Prediction of severity in acute pancreatitis 
Even though the initiating cause in acute pancreatitis is varied, the cascade of events that follows 
is quite similar, irrespective of etiology. The disease can vary from a mild self-limited illness with 
an extremely good prognosis to one in which there is multi organ dysfunction, high morbidity and 
mortality. In India, where resources in terms of ICU beds and intensive care physicians are scarce, 
predicting severity and course of pancreatitis is all the more relevant to allocate existing resources 
prudently 
 
7.3 Currently available predictors 
Pancreatitis is classified as severe when there are local or systemic complications with persistent 
multi organ dysfunction. In practice, the Ranson’s and APACHE II scores are used to assess the 
severity of illness and predict prognosis. The other commonly used parameters that correlate with 
patient outcome are CRP measured at 48-72 hours and CT scan done after 48 hours, from onset of 
pain. Many other biomarkers have been studied as predictors of severity. Many have good 
sensitivity but suffer from poor specificity. With only a minority of acute pancreatitis being 
severe (20%), the predictive value of a positive test is low. Thus, none of the biomarkers have 
been shown to robustly predict the course of illness in pancreatitis. Often close and repeated 
monitoring for any change in the patient’s vital parameters is the best clue to the course of illness. 
 
7.4 Hydrogen sulphide 
H2S has been found in recent years to be an important gasotransmitter, along with nitric oxide 
and carbon monoxide. The measurement of hydrogen sulphide has to be carried out immediately 
after collection due to its volatile nature. The colorimetric method used in this study measures by 
spectrophotometry, the amount of methylene blue produced. Methylene blue can form dimers 
and trimers in a concentration dependent manner which affects the estimation of H2S. Therefore 
when this method is used, it has to be validated by measuring the monomer to dimer equilibrium 
in patient and control samples. Some samples could not be analysed in the study due to the 
inability to carry out the test on stored samples and due to the presence of sample hemolysis. 
 
7.5 Animal studies 
Animal studies have shown that hydrogen sulphide levels correlate with severity of pancreatitis 
and acute lung injury, and that attenuation of the H2S production led to a less severe forms of 
pancreatitis and lung injury. In animal studies, the uniform age of the animal, the controlled 
degree of artificial pancreatic insult, the ability to estimate H2S early in the illness and the 
uniformity of sampling times gave reproducible results. This study was undertaken in order to 
assess the role of hydrogen sulphide in acute pancreatitis and to test its applicability in a routine 
clinical setting. 
 
7.6 Human studies 
Contrary to findings in animal studies, our study did not validate the usefulness of H2S as a 
marker of severity in acute pancreatitis in the clinical setting. There was also no correlation found 
between H2S and CRP levels.  
 
The differences in etiology, severity of insult, duration of illness, development of complications, 
genetic variations in inflammatory response and other unmeasured variables produced a wide 
range of H2S values, rendering the test unhelpful. It is likely that similar problems exist in other 
biomarker studies. Tests which perform well in animal studies often do poorly in human studies, 
leading to negative studies and non-publication. This can also explain the lack of published 
human studies in the usefulness of H2S as a predictor of severity in acute pancreatitis. Aside from 
a single published abstract (Eric WL Wee et al AGA Gastroenterology Volume 136,Issue 
5,supplement 1,May 2009), this study is  the first  to study the role of hydrogen sulphide in cases 
of acute pancreatitis in humans in a routine  clinical scenario where  patients seek medical care 
after at varied time points following the onset of disease. 
 
7.7 Post-hoc analysis of early presenters 
In the study conducted by Eric WL Wee et al, which showed that H2S was a very good predictor 
of severity, only patients who presented within 72 hrs of onset of symptoms were included. 
Serum H2S levels may not correlate with the severity of pancreatitis in patients who present 
several days after onset of pain, as seen in routine clinical practice. The majority of the patients 
in the current study presented more than 3 days after onset of pain. We looked at the subgroup of 
patients who presented early in course of illness i.e. within 3 and 4 days after onset of pain. We 
did not find a significant difference in this subgroup of patients, with mild and severe acute 
pancreatitis. 
 
 
7.8 Assessment after 48 hours 
The purpose of estimating the values of H2S at 48 hrs was to assess the patient after fluid 
resuscitation and providing adequate analgesia. H2S levels were not significantly different 
between cases of mild and severe pancreatitis, at 48hours after admission. We also analysed 
whether temporal trends in H2S could provide prognostic data. We predicted that patients with a 
mild disease course would show a decrease in levels. This was not borne out on analysis. On the 
contrary, many patients had increase in H2S levels despite clinical improvement. 
 
7.9 Therapeutic blocking of hydrogen sulphide production 
Previously, Madhav Bhatia et al demonstrated that administration of PAG (propargylglycine), a 
CSE inhibitor, protected mice against severe pancreatitis and lung injury. The therapeutic 
potential of H2S modulation may be realised in the prevention of post-ERCP pancreatitis, where 
the initiating event occurs in the hospital and treatment before onset or early in the illness can be 
given. 
 
7.10 Limitations of this study 
The intrinsic instability of H2S and the lack of fully automated assays resulted in problems with 
estimation. The stringency of the sample requirements resulted in a loss of recruitment - due to 
delay in sample collection and transport, suboptimal sample quality due to hemolysis, weekend 
admissions and non-availability of 24 hour laboratory facilities.We excluded samples which could 
not be processed immediately and did not study the effect that delay in sample testing would have 
on H2S estimates. 
 
Our hospital is a tertiary referral centre, and a higher proportion of cases had severe acute 
pancreatitis. Often, patients had received treatment prior to admission to our hospital. Though the 
results may not have been different, it should be kept in mind that it was a single centre study 
with a high proportion of severe cases. 
 
 
7.11 Conclusions 
There was no difference in admission and 48 H2S levels between mild and severe pancreatitis. 
Levels of H2S did not correlate with systemic complications (ALI, AKI and sepsis), or mortality. 
Temporal trends of H2S in the initial days of admission were also not found to be helpful. 
The present study could not establish hydrogen sulphide as a marker of severity of acute 
pancreatitis. Futures studies grouping patients according to time of presentation may clarify its 
usefulness in patient subgroups. 
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                                                                    APPENDIX 1 
                                                       PROFORMA 
 
     NAME                                                                                                               HOSPITAL NO. 
     AGE                                                                                                                   ADDRESS- 
     SEX                                                                                                                    OCCUPATION- 
     D.O.A -                                 D.O.D - 
 
CHIEF COMPLAINTS                                                                                     DURATION    
 
                            1.                                                                                      
                            2.       
                            3. 
                            4.       
HISTORY OF PRESENT ILLNESS 
PAST HISTORY 
PERSONAL HISTORY 
 
GENERAL EXAMINATION- 
 
Wt-                         Ht-                        BMI 
VITALS-  
PR-                          BP-                       RR-                          SPO2- 
 
P/A-                                          RESP                                    CNS                                   CVS 
INVESTIGATION- AT ADMISSION                                                                         AFTER 48 Hrs 
CBC  -Hb-                                                       CRP                                                               CBC    Hb- 
TC -               DC  -                                          LDH                                                                         TC-              DC- 
Hct-                                                                                                                                                 Hct_ 
 LFT                                                                  Ca                                                                  CREATININE 
 CREATININE                                                  FASTING LIPID PROFILE 
UREA                                                              TG                        CH 
NA/K                                                               LDL                                                                 ABG 
BBVS                                                               AMYLASE- 
CXR-                                                                LIPASE- 
CULTURES 
ABG- 
USG ABDOMEN- 
 ICU STAY(DAYS) -                                                                    MECHANICAL VENTILATOR REQUIREMENT- 
 
CECT ABDOMEN- 
 
BALTHAZAR   STAGING- 
ORGAN FAILURE 
BISAP SCORE- 
RANSONS SCORE- 
DIAGNOSIS-         
SEVERITY OF ACUTE PANCREATITIS— 
                                               HYDROGEN SULFIDE LEVELS 
AT ADMISSION                                  AFTER 48 HOURS                                 AT DISCHARG 
                                                                    APPENDIX-2 
                                                                  MASTER CHART 
S.NO. HNUM AGE(yrs) SEX SEVERITY H2S ADM 
H2S 
48HRS H2S AT D ALI AKI 
1 291368 F      31 1 2 37.86 50.71 38.57 1 2 
2 281093 F       19 2 1 38.57 27.14 2 2 
3 194104 F      43 1 1 36.43 38.57 36.43 2 2 
4 546009 C      73 1 1 28.57 46.07 2 2 
5 290269 F 38 1 1 76.43 57.86 2 2 
6 329012 F 29 2 1 7.14 3.57 7.14 2 2 
7 309641 F 29 1 2 6.07 1 2 
8 327517 F 27 1 1 7.86 2 2 
9 342730 F 44 2 1 11.43 8.93 9.28 2 2 
10 373384 A 65 1 1 15 10.71 10.71 2 2 
11 554522 B 50 1 2 46.43 22.86 17.86 1 1 
12 374333 F 29 1 2 10 1 1 
13 367979 F 31 1 1 12.14 16.43 11.43 2 2 
14 374526 F 36 1 2 12.14 15 9.64 1 2 
15 373239 F 66 2 1 15.71 19.28 16.43 2 2 
16 361242 F 40 1 1 21.43 14.28 2 2 
17 246773 F 26 1 1 20.71 16.43 2 2 
18 389154 F 41 1 2 35.71 37.14 22.14 1 2 
19 384699 F 43 1 2 15 10 5 1 2 
20 389094 F 36 1 1 14.28 2 2 
21 315187 F 49 1 1 11.43 12.86 11.43 2 2 
22 013331 F 52 2 2 14.28 10.58 12.14 1 2 
23 401398 F 66 1 1 12.86 13.93 2 2 
24 401388 F 49 1 1 15 12.86 2 2 
25 406258 F 46 1 2 42.86 21.43 10.71 1 2 
26 379541 F 21 2 1 11.78 12.86 12.14 2 2 
27 415599 F 32 1 1 15.71 14.28 12.14 2 2 
28 566953 D 64 1 1 17.14 15 16.43 2 2 
29 422515 F 32 1 2 36.43 37.14 34.28 1 2 
30 434377 F 29 2 1 11.5 12.75 2 2 
31 422613 F 28 1 2 13.57 11.78 1 2 
32 434625 F 34 1 1 81.43 2 2 
33 434120 F 63 1 2 54.28 59.28 87.86 1 2 
34 441047 F 39 1 1 76.43 72.86 91.43 2 2 
35 028262 D 28 2 1 65 62.86 2 2 
36 448324 F 59 1 1 47.14 54.28 54.28 2 2 
37 448492 F 71 1 2 53.21 72.86 2 2 
38 471690 F 38 1 2 56 67 65 2 2 
39 455700 F 33 1 2 47.21 57.28 54.28 2 2 
40 455941 F 34 1 2 37.14 30.25 42.14 1 2 
41 374526 F 35 1 2 19.15 20.16 19.28 1 2 
42 072576 F 24 2 1 25.57 20.57 23.12 2 2 
43 474374 F 27 1 2 12.56 10 21.86 1 2 
44 703980 A 38 1 1 45.14 47.28 47.14 2 2 
45 474434 F 27 1 1 13.14 12.28 11.54 2 2 
46 664561 F 39 1 1 26.78 20.12 2 2 
47 604983 58 2 2 74.43 70.86 50.28 1 1 
48 611960 F 55 2 1 16.14 24.15 20.86 2 2 
49 701361 A 80 1 2 16.78 20.58 17.26 1 2 
50 657780 F 18 2 1 12.14 11.21 11.86 2 2 
51 582566 D 22 1 1 52.21 54.28 47.81 2 2 
52 479777 F 65 2 1 38.57 35.56 2 2 
53 657667 F 80 1 2 26.71 20.16 2 1 
54 651775 F 27 1 2 15.26 26.17 1 2 
55 639560 F 35 1 2 47.28 32.14 1 1 
 
 
S.NO. HNUM 
ETIOLOGY 
DAY  OF 
PAIN 
AND IST 
SAMPLE CRP LDH DURATION 
ICU 
STAY VENTILATION BMI 
1 291368 F       
A 5  897 19 3 0 24.1 
2 281093 F       
O 3  446 6 0 0 22.4 
3 194104 F       
O 3 63.4 586 6 0 0 20.9 
4 546009 C      
B 2  437 8 0 0 22.9 
5 290269 F 
A 4 65.6 495 10 0 0 26.8 
6 329012 F 
O 4 92.2 335 10 8 0 33.2 
7 309641 F 
O 5 115 450 12 0 0 26.4 
8 327517 F 
A 2 30.9 394 4 0 0 28.5 
9 342730 F 
B 6 6.94 716 9 0 0 20.3 
10 373384 A 
A 2 176 643 5 0 0 20.8 
11 554522 B 
A 4 204 838 7 6 0 33.2 
12 374333 F 
A 2  3475 1 1 1 30.8 
13 367979 F 
A 3 89.1 270 5 4 0 33.5 
14 374526 F 
A 6 154 778 4 3 0 24.8 
15 373239 F 
B 6 12.4 2595 7 0 0 36.8 
16 361242 F 
A 6 45.2 271 3 0 0 21.3 
17 246773 F 
A 2 114 367 4 0 0 21.5 
18 389154 F 
A 2 204 909 7 2 0 21 
19 384699 F 
A 6 204 815 10 3 0 25.9 
20 389094 F 
A 3 44.3 392 4 0 0 24 
21 315187 F 
B 3 6.03 925 11 0 0 23.2 
22 013331 F 
O 3 76.2 462 5 2 0 27.9 
23 401398 F 
O 2 76.9 507 4 0 0 23 
24 401388 F 
B 5 204 1068 6 0 0 27.1 
25 406258 F 
B 4  757 13 0 0 22 
26 379541 F 
B 4 29.3 267 7 0 0 30.8 
27 415599 F 
B 2 4.78 781 11 0 0 25.8 
28 566953 D 
B 1  607 6 0 0 18.9 
29 422515 F 
A 2 204 178 11 10 0 21.4 
30 434377 F 
O 5 3.19 235 2 0 0 19 
31 422613 F 
A 3 204 1820 20 19 1 25.2 
32 434625 F 
A 5 12.8 776 3 0 0 21 
33 434120 F 
O 2 26.1 350 10 6 0 23.2 
34 441047 F 
A 3 106 502 6 0 0 26.3 
35 028262 D 
O 1   6 2 0 21 
36 448324 F 
B 3  452 6 0 0 27 
37 448492 F 
A 3 124 608 6 0 0 22.6 
38 471690 F 
O 2 125 266 8 0 0 25 
39 455700 F 
A 2 129 1142 4 0 0 22 
40 455941 F 
A 3 204 887 12 3 0 26 
41 374526 F 
A 3 204  5 4 0 24.8 
42 072576 F 
B 3 5.07 540 3 0 0 20 
43 474374 F 
A 5 204 930 10 9 0 26.2 
44 703980 A 
A 3 34.2 1195 5 0 0 25 
45 474434 F 
B 5 118 733 4 0 0 25.4 
46 664561 F 
A 3 152 703.9 3 0 0 23.6 
47 604983 
O 4 4.32 486 8 7 0 27.2 
48 611960 F 
B 5 105 347 9 0 0 23.4 
49 701361 A 
O 3 186  15 7 0 24.4 
50 657780 F 
O 3  298 4 0 0 18.2 
51 582566 D 
B 3 108 432 3 0 0 22 
52 479777 F 
B 2   11 0 0 23 
53 657667 F 
O 3  257 4 0 0 22.4 
54 651775 F 
O 2 221 958 7 4 0 25.4 
55 639560 F 
A 3  400 22 22 1 26.2 
 
S.NO. HNUM 
1 291368 F      
SEPSIS 
LOCAL 
COLLECTION VASCULAR  DEATH 
2 281093 F       
1 1 2 0 
3 194104 F      
0 2 2 0 
4 546009 C      
0 2 2 0 
5 290269 F 
1 2 2 0 
6 329012 F 
0 2 2 0 
7 309641 F 
0 2 2 0 
8 327517 F 
0 2 2 0 
9 342730 F 
0 2 2 0 
10 373384 A 
1 2 2 0 
11 554522 B 
0 2 2 0 
12 374333 F 
1 1 2 0 
13 367979 F 
1 2 2 1 
14 374526 F 
0 2 2 0 
15 373239 F 
0 1 2 0 
16 361242 F 
0 2 2 0 
17 246773 F 
0 2 2 0 
18 389154 F 
0 2 2 0 
19 384699 F 
0 2 1 0 
20 389094 F 
1 2 2 0 
21 315187 F 
0 2 2 0 
22 013331 F 
1 2 2 0 
23 401398 F 
1 2 2 0 
24 401388 F 
0 2 2 0 
25 406258 F 
0 2 2 0 
26 379541 F 
0 1 2 0 
27 415599 F 
0 2 2 0 
28 566953 D 
1 2 2 0 
29 422515 F 
1 2 2 0 
30 434377 F 
1 1 2 0 
31 422613 F 
0 2 2 0 
32 434625 F 
0 1 2 0 
33 434120 F 
0 2 2 0 
34 441047 F 
1 1 2 0 
35 028262 D 
1 2 2 0 
36 448324 F 
0 2 2 0 
37 448492 F 
0 2 2 0 
38 471690 F 
 2 1 0 
39 455700 F 
1 1 2 0 
40 455941 F 
1 1 2 0 
41 374526 F 
1 1 2 0 
42 072576 F 
1 2 2 0 
43 474374 F 
0 2 2 0 
44 703980 A 
1 1 2 0 
45 474434 F 
0 2 2 0 
46 664561 F 
0 2 2 0 
47 604983 
0 2 2 0 
48 611960 F 
1 2 2 0 
49 701361 A 
0 2 2 0 
50 657780 F 
1 1 2 0 
51 582566 D 
0 2 2 0 
52 479777 F 
0 2 2 0 
53 657667 F 
1 2 2 0 
54 651775 F 
0 2 2 0 
55 639560 F 
0 2 2 0 
  
1 1 2 1 
 
 
Male-1 
 
ALI-Acute lung injury Etiology 
 
Sepsis Vascular complication 
female-
2 
 
Yes-1 
  
A -alcohol Yes-1 Yes-1 
 
  
No-2 
  
B-Biliary 
 
No-0 No-2 
 
Mild-1 
 
Acute kidney injury 
 
O-
Others 
    Severe-
2 
 
Yes-1 
    
Local complication Death 
  
No-2 
    
Yes-1 
 
yes-1 
       
No-2 
 
No-0 
 
 
  
